Merck KGaA’s share price did not have any implicit value for Cladribine, so there was no value to lose on account of the BG-12 data. Rebif (and the other interferons) will continue to do ok.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”